Composition for contraception
First Claim
Patent Images
1. A combination product for oral contraception, comprising(a) 23 or 24 dosage units, each containing an estrogen selected from>
- 2.0 to 6.0 mg of 17β
-estradiol and0.020 mg of ethinylestradiol;
and a gestagen selected from0.25 to 0.30 mg of drospirenone and0.1 to 0.2 mg of cyproterone acetate,andb) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days.
2 Assignments
0 Petitions
Accused Products
Abstract
A combination product for oral contraception is disclosed comprising an estrogen selected from
2.0 to 6.0 mg of 17β-estradiol and
0.020 mg of ethinylestradiol;
and a gestagen selected from
0.25 to 0.30 mg of drospirenone and
0.1 to 0.2 mg of cyproterone acetate,
followed by 5 or 4 pill-free or sugar pill days.
21 Citations
10 Claims
-
1. A combination product for oral contraception, comprising
(a) 23 or 24 dosage units, each containing an estrogen selected from > - 2.0 to 6.0 mg of 17β
-estradiol and0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, and b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 2.0 to 6.0 mg of 17β
Specification